CClinicalTrials.gg
Active, not recruitingNCT03409718Updated Jul 10, 2026

Database Retrieval for the Comprehensive Shoulder

An observational study in Osteoarthritis of the Shoulder, Avascular Necrosis and Rheumatoid Arthritis, sponsored by Zimmer Biomet. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Zimmer Biomet · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Study summary

This study is a retrieval of database information regarding survivorship of the Comprehensive Shoulder System family of products. The primary objective of the retrieval is to collect data that will contribute to the post market surveillance requirements for this product and will provide feedback to design engineers, support marketing efforts and publications, and answer potential questions form reimbursement agencies.

Read the detailed description

The Comprehensive Shoulder System has been cleared by the FDA via premarket notifications. No experimental or investigational surgical techniques or devices will be used in this study. All devices and products will be used in accordance with their instructions for use and/or approved labeling. The aim of the Comprehensive Shoulder System is to improve shoulder function and reduce pain.

One site will be used for this database retrieval. The number of patients involved will depend upon the size of the Comprehensive database available at Acromion, LLC.

02

Conditions studied

  • Osteoarthritis of the Shoulder
  • Avascular Necrosis
  • Rheumatoid Arthritis
  • Prior Failed Revision
  • Correction of Functional Deformity
  • Fracture of Proximal End of Humerus
  • Cuff Tear Arthropathy

Keywords

  • Total Shoulder Arthroplasty
  • Medical Device
  • Performance
  • Safety
  • Shoulder Prosthesis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients in need of a total shoulder arthroplasty which receive one of the devices in the Comprehensive Shoulder family and who meet all of the inclusion and none of the exclusion criteria.

Inclusion criteria

  • Must have one of the following indications:
  • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
  • Rheumatoid arthritis
  • Revision where other devices or treatments have failed.
  • Correction of functional deformity.
  • Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.
  • Difficult clinical management problems, including cuff arthropathy, where other methods of treatment may not be suitable or may be inadequate.
  • Need to obtain pain relief and improve function
  • Ability and willingness of the patient to follow instructions, including control of weight and activity level
  • A good nutritional state of the patient
  • The patient must have reached full skeletal maturity

Exclusion criteria

Exclusion Criteria:

  • Absolute contraindications include infection, sepsis, and osteomyelitis.
  • Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.
  • Osteoporosis.
  • Metabolic disorders which may impair bone formation.
  • Osteomalacia.
  • Distant foci of infections which may spread to the implant site.
  • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (actual)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Biomet Comprehensive Shoulder System

    Subjects in need of a total shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Shoulder System.

    Device: Biomet Comprehensive Shoulder System

Interventions

  • DeviceBiomet Comprehensive Shoulder System

    Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform

05

What researchers measure

Primary outcomes

  1. Implant survivorship is assessed counting the number of implant revisions

    Implant survivorship will be documented by assessing the number of implant revisions occurring throughout the course of the study.

    Time frame: 10 years

Secondary outcomes

  1. Constant Shoulder Score

    The Constant-Murley Shoulder Score is a scoring method used by clinicians to assess function of the shoulder. The standard score is on a scale of 0 to 100, with 0 being no shoulder function and 100 being excellent function.

    Time frame: 10 years

  2. Clinical Safety

    Clinical safety is assessed through documentation of complications occurring during the course of the study.

    Time frame: 10 years

  3. Clinical Safety - Device Related

    Clinical safety is assessed through documentation of device-related events occurring during the course of the study.

    Time frame: 10 years

06

Study locations

1 site
  • Acromion LLC
    Towson, Maryland 21204, United States
07

Registry details

Key details

Study ID
NCT03409718
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Feb 24, 2011
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 10, 2026

Study contacts

Erin D Osborn
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion